Core Viewpoint - The ALPS Sector Dividend Dogs ETF (SDOG) employs a classic income strategy by selecting the highest-yielding stocks across various sectors, providing a diversified approach to capturing dividends without focusing solely on traditional income-heavy sectors like utilities or real estate [1] Summary by Relevant Sections Fund Overview - SDOG manages $1.25 billion in assets and has achieved a year-to-date return of 10.1% [1] - The fund utilizes the "Dogs of the Dow" strategy, selecting the five highest-yielding stocks from 10 of the 11 Global Industry Classification Standard sectors, excluding real estate [1] Dividend Yield and Sector Allocation - The underlying index of SDOG has a trailing twelve-month dividend yield of 3.68%, significantly higher than the S&P 500's yield of 1.09% [1] - SDOG holds overweight positions in income-focused sectors, with 8.06% more in utilities, 7.90% more in materials, and 7.18% more in energy compared to the S&P 500 [1] Valuation and Holdings - SDOG's underlying index has a price-to-earnings ratio of 17.90, lower than the S&P 500's ratio of 28.13 [1] - Current holdings include companies from various sectors such as technology (Seagate Technology Holdings, International Business Machines Corp.), energy (Exxon Mobil Corp., Chevron Corp.), and pharmaceuticals (Pfizer Inc., AbbVie Inc.) [1] Investment Strategy - The equal-weight methodology of SDOG mitigates concentration risk associated with market-cap-weighted approaches, with 52 positions spread across its 10 target sectors [1]

Thinkstock Quick Read After a brutal Monday, investors were treated to a snap-back rally in stocks on Tuesday. All of the major indices and Cryptocurrencies finished the day higher on Tuesday as hopes for an interest rate cut remained positive. If the Fed does lower rates next week, that could be the catalyst to kick off an end-of-the-year “Santa Claus Rally.” Some investors get rich while others struggle because they never learned there are two completely different strategies to building wealth. ...

Core Insights - Silver prices are experiencing a significant rally, reaching new highs of $58.58 an ounce, with year-to-date gains nearing 100% [1] - The tightening global supply of silver, particularly due to recent flows into London's market, is contributing to higher prices and borrowing costs [1] - A potential interest rate cut by the Federal Reserve could further boost silver as a safe haven asset [1] Silver Market Dynamics - The current winter season is favorable for silver prices, with strong performance noted at the beginning of December [1] - The supply constraints in markets like Shanghai are exacerbating the tight supply situation [1] Investment Opportunities - Investors can capitalize on the silver rally through ETFs, such as the Sprott Physical Silver Trust (PSLV), which has seen a year-to-date NAV increase of 66.69% as of October 31, 2025 [1] - The Sprott Silver Miners & Physical Silver ETF (SLVR) offers exposure to both physical silver and the mining industry, with a NAV increase of 46.10% over the last three months as of November 30, 2025 [1]

Core Insights - The cryptocurrency market, particularly altcoins, has not consistently delivered on its promise, highlighting the need for selective investment strategies [1] - The CoinShares Altcoins ETF (DIME) is positioned as a potentially valuable tool for investors in the altcoin space, being actively managed and focused on higher market capitalization altcoins [1] - The Federal Reserve's shift away from quantitative tightening (QT) could positively influence altcoin performance, as historical trends suggest altcoins thrive during periods without QT [1] Group 1 - DIME is a new actively managed ETF that targets higher market capitalization altcoins, which are less speculative compared to the broader altcoin universe [1] - Historical data indicates that during periods of no QT, altcoins experienced significant uptrends, with notable growth observed from 2014 to 2017 and 2019 to 2022 [1] - The Fed's current monetary policy, including two rate cuts in 2025 and expectations for another, may create a favorable environment for altcoin investments [1] Group 2 - Research by analyst Matthew Hyland suggests that the absence of QT has historically allowed altcoins to sustain uptrends for 42 months (2014-2017) and 29 months (2019-2022) [1] - The Fed's liquidity policy is identified as a core influence on the performance of crypto risk assets, indicating that declining rates could enhance the case for altcoin exposure [1] - The article emphasizes that while the end of rate hiking cycles does not guarantee immediate looser monetary policy, the current scenario of declining rates could be beneficial for altcoin investors [1]

Time now for Options Corner. Joining us to take a deeper look at this chart is Rick Dukat, Duke of Data himself. So Rick, when you take a look at this chart, what are the trends you pay attention to, especially given that strong outperformance this year.>> Yes, exactly. Uh backing off a little bit from the highs, but seemingly on the move once again to the upside here, uh handily outperforming the tech sector and the S&P 500, up about uh 47 a.5% so far uh during the past year. When we look at some of these ...

Core Insights - Longeveron Inc. is participating in the Global CardioVascular Clinical Trialists Forum, highlighting its focus on cellular therapies for serious medical conditions [2][3] Company Overview - Longeveron Inc. is a clinical stage biotechnology company developing regenerative medicines to address unmet medical needs [4] - The company's lead investigational product is laromestrocel (Lomecel-B®), an allogeneic mesenchymal stem cell therapy derived from the bone marrow of young, healthy adult donors [4] - Laromestrocel has multiple potential mechanisms of action, including pro-vascular, pro-regenerative, anti-inflammatory, and tissue repair effects, with applications across various disease areas [4] - The company is pursuing three pipeline indications: hypoplastic left heart syndrome (HLHS), Alzheimer's disease, and Pediatric Dilated Cardiomyopathy (DCM) [4] - Laromestrocel has received five important FDA designations, including Orphan Drug, Fast Track, and Rare Pediatric Disease designations for the HLHS program, and Regenerative Medicine Advanced Therapy (RMAT) and Fast Track designations for the Alzheimer's program [4] Event Participation - Dr. Joshua Hare and Dr. Nataliya Agafonova will participate in multiple panel discussions at the CVCT Forum, focusing on cell therapy in heart failure trials and the importance of cell delivery routes [2][3] - Specific topics include mesenchymal stem cell therapy for dilated cardiomyopathy and strategies to streamline cell therapy innovation [3]

GREEN DOT SHAREHOLDER ALERT: Kaskela Law LLC Announces Investigation of Green Dot Corporation (GDOT) and Encourages Investors to Contact the Firm to Discuss Their Legal Rights and Options - GDOTDecember 03, 2025 9:15 AM EST | Source: Kaskela Law LLCPhiladelphia, Pennsylvania--(Newsfile Corp. - December 3, 2025) - Kaskela Law LLC announces that it is investigating the recently announced proposed acquisition of Green Dot Corporation (NYSE: GDOT) to determine whether the transaction as structured ...

COMERICA SHAREHOLDER LAWSUIT FILED: Kaskela Law LLC Encourages Comerica (CMA) Shareholders to Contact the Firm for Additional Information About Their Legal Rights and OptionsDecember 03, 2025 9:15 AM EST | Source: Kaskela Law LLCPhiladelphia, Pennsylvania--(Newsfile Corp. - December 3, 2025) - The law firm of Kaskela Law LLC hereby notifies Comerica Inc. (NYSE: CMA) investors that a shareholder class action lawsuit has been filed in connection with the company's proposed acquisition by Fifth T ...

LEGAL ALERT: Kaskela Law LLC Announces Investigation of Electronic Arts Inc. (EA) and Encourages EA Shareholders to Contact the Firm to Discuss Their Legal Rights and Options Before the Voting DeadlineDecember 03, 2025 9:15 AM EST | Source: Kaskela Law LLCPhiladelphia, Pennsylvania--(Newsfile Corp. - December 3, 2025) - Kaskela Law LLC is investigating the proposed buyout of Electronic Arts Inc. (NASDAQ: EA) ("EA" or the "Company") shareholders to determine whether the buyout agreement is fair ...

Core Insights - Microsoft has reduced sales growth targets for certain artificial intelligence products due to underperformance by sales staff in the fiscal year ending in June [1] Group 1: Sales Performance - Multiple divisions within Microsoft have reported that sales staff missed their sales goals, leading to a reassessment of growth expectations for AI products [1] - The adjustments in sales targets reflect challenges faced in achieving projected sales figures, indicating potential issues in market demand or sales strategy [1] Group 2: Impact on AI Products - The lowered sales growth targets may affect the overall revenue projections for Microsoft's AI product lines, which are critical to the company's future growth strategy [1] - This development highlights the competitive landscape in the AI sector, where achieving sales targets is increasingly challenging [1]